+357 96 030922
info@marketpublishers.com

Global Urea Cycle Disorder (UCD) Drugs Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GEE90C41A55EEN.html
Date: September 2026
Pages: 111
Price: US$ 4,480.00 (Single User License)
ID: GEE90C41A55EEN

Abstracts

The global Urea Cycle Disorder (UCD) Drugs market size is expected to reach $ 1437 million by 2032, rising at a market growth of 10.5% CAGR during the forecast period (2026-2032).

Urea cycle disorder (UCD) drugs are prescription medicines used to treat inherited metabolic diseases caused by deficiencies in urea-cycle enzymes or related transport proteins. These therapies reduce ammonia and other toxic metabolites by establishing alternative nitrogen-excretion pathways, activating residual urea-cycle function, replacing deficient enzyme activity or restoring the underlying genetic function, thereby reducing hyperammonemic crises, neurological injury and related hospitalization risks. Major products include glycerol phenylbutyrate, sodium phenylbutyrate, intravenous sodium phenylacetate and sodium benzoate, carglumic acid, pegylated arginase, as well as investigational gene therapies, mRNA therapies and gene-editing treatments. Key upstream inputs include phenylbutyric acid and its derivatives, glycerol, sodium benzoate, carglumic acid API, recombinant cell lines, culture media, purification resins, PEG-modification reagents, plasmids, AAV vectors, nucleotides, lipid nanoparticle materials, sterile excipients and pharmaceutical packaging. Major downstream channels include inherited-metabolic-disease centers, children's hospitals, general hospitals, specialty pharmacies and rare-disease distributors. The industry is characterized by a limited patient population, high treatment value per patient, stable long-term demand and substantial regulatory and commercialization barriers, with an estimated blended gross margin of approximately 70%–84%.

From the demand perspective, the urea cycle disorder drug market is expected to maintain steady growth, supported by broader newborn screening, wider use of genetic testing, improved inherited-metabolic-disease care networks and longer patient survival.

+357 96 030922
info@marketpublishers.com

Better identification of late-onset, mild and atypical cases will increase the number of patients receiving long-term treatment. Current demand remains concentrated in nitrogen scavengers and medicines used for acute hyperammonemic crises, while wider use of subtype-specific therapies for NAGS deficiency, ARG1 deficiency and other conditions will increase treatment depth and value per patient. Improved access, local production and reimbursement support in China and other emerging markets will also contribute to incremental demand.

From a product perspective, nitrogen scavengers will remain the foundation of treatment for most patients in the foreseeable future, although innovation is gradually shifting from metabolic bypass control toward subtype-specific and disease-modifying therapies. Conventional products will increasingly compete on palatability, formulation convenience, pediatric suitability, dosing burden and long-term adherence, while enzyme-replacement therapies may establish clearer positions in patients with specific enzymatic deficiencies. Gene therapy, mRNA therapy and in vivo gene-insertion technologies are also being developed to restore sustained expression of deficient enzymes and could materially reduce dietary restrictions and lifelong dependence on nitrogen-scavenger therapy if durable efficacy and acceptable safety are demonstrated.

From the competitive perspective, the commercial market remains concentrated among a limited number of companies with established nitrogen-scavenger brands, rare-disease distribution channels and specialized patient-support systems. The entry of conventional and authorized generics will increase pricing and market-share pressure on premium brands, although products with differentiated formulations, pediatric advantages, subtype-specific indications and strong global market-access capabilities may retain meaningful positions. Competition will gradually shift from simple ammonia reduction toward prevention of hyperammonemic crises, improvement of neurological outcomes, reduction of hospitalization and enhancement of quality of life. Companies combining innovative technology platforms with long-term patient-management capabilities are likely to gain a stronger position.

From the risk perspective, individual UCD subtypes have small patient populations and highly variable clinical presentations, making drug development vulnerable to recruitment difficulties, natural disease fluctuation and complex endpoint design. Gene therapies must still address immune responses, liver-safety concerns, loss of efficacy during pediatric growth and limited repeat-dosing options, while mRNA therapies face challenges associated with repeated intravenous administration and long-term delivery-system tolerability. High-cost one-time therapies will also face close scrutiny regarding affordability, durability and risk-sharing arrangements. Over the longer term, the market

+357 96 030922
info@marketpublishers.com

is expected to develop into a mixed structure of conventional nitrogen scavengers, subtype-specific medicines and disease-modifying therapies, with long-term efficacy, treatment burden, affordability and lifecycle patient management becoming the main determinants of product value.

Report Scope

This report studies the global Urea Cycle Disorder (UCD) Drugs demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Urea Cycle Disorder (UCD) Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Urea Cycle Disorder (UCD) Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Urea Cycle Disorder (UCD) Drugs total market, 2021-2032, (USD Million)

Global Urea Cycle Disorder (UCD) Drugs total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Urea Cycle Disorder (UCD) Drugs total market, key domestic companies, and share, (USD Million)

Global Urea Cycle Disorder (UCD) Drugs revenue by player, revenue and market share 2021-2026, (USD Million)

Global Urea Cycle Disorder (UCD) Drugs total market by Type, CAGR, 2021-2032, (USD Million)

Global Urea Cycle Disorder (UCD) Drugs total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Urea Cycle Disorder (UCD) Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a

+357 96 030922
info@marketpublishers.com

part of this study include Amgen, Ucyclyd Pharma, Recordati, Immedica Pharma, MPerium, Medunik, Zevra Therapeutics, Mallinckrodt, Lupin, Grand Pharmaceutical Group, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Urea Cycle Disorder (UCD) Drugs market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Urea Cycle Disorder (UCD) Drugs Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Urea Cycle Disorder (UCD) Drugs Market, Segmentation by Type:

+357 96 030922
info@marketpublishers.com

Nitrogen Scavengers

Urea Cycle Activators

Enzyme Therapies

Other

Global Urea Cycle Disorder (UCD) Drugs Market, Segmentation by Active Ingredient:

Glycerol Phenylbutyrate

Sodium Phenylbutyrate

Sodium Phenylacetate and Benzoate

Carglumic Acid

Other

Global Urea Cycle Disorder (UCD) Drugs Market, Segmentation by Administration Route:

Oral

Intravenous

Subcutaneous

Global Urea Cycle Disorder (UCD) Drugs Market, Segmentation by Application:

Hospital

+357 96 030922
info@marketpublishers.com

Clinic

Other

Companies Profiled:

Amgen

Ucyclyd Pharma

Recordati

Immedica Pharma

MPerium

Medunik

Zevra Therapeutics

Mallinckrodt

Lupin

Grand Pharmaceutical Group

Lee's Pharmaceutical Holdings

Winhealth Pharma Group

Ultragenyx

Arcturus Therapeutics

iECURE

+357 96 030922
info@marketpublishers.com

Key Questions Answered

1. How big is the global Urea Cycle Disorder (UCD) Drugs market?
2. What is the demand of the global Urea Cycle Disorder (UCD) Drugs market?
3. What is the year over year growth of the global Urea Cycle Disorder (UCD) Drugs market?
4. What is the total value of the global Urea Cycle Disorder (UCD) Drugs market?
5. Who are the Major Players in the global Urea Cycle Disorder (UCD) Drugs market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY
1.1 Urea Cycle Disorder (UCD) Drugs Introduction
1.2 World Urea Cycle Disorder (UCD) Drugs Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Urea Cycle Disorder (UCD) Drugs Total Market by Region (by Headquarter Location)
  1.3.1 World Urea Cycle Disorder (UCD) Drugs Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032)
  1.3.3 China Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032)
  1.3.4 Europe Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032)
  1.3.5 Japan Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032)
  1.3.6 South Korea Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032)
  1.3.7 ASEAN Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032)
  1.3.8 India Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Urea Cycle Disorder (UCD) Drugs Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY
2.1 World Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032)
2.2 World Urea Cycle Disorder (UCD) Drugs Consumption Value by Region
  2.2.1 World Urea Cycle Disorder (UCD) Drugs Consumption Value by Region (2021-2026)
  2.2.2 World Urea Cycle Disorder (UCD) Drugs Consumption Value Forecast by Region (2027-2032)
2.3 United States Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032)
2.4 China Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032)
2.5 Europe Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032)
2.6 Japan Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032)
2.7 South Korea Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032)
2.8 ASEAN Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032)

+357 96 030922
info@marketpublishers.com

2.9 India Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032)

3 WORLD UREA CYCLE DISORDER (UCD) DRUGS COMPANIES COMPETITIVE ANALYSIS
3.1 World Urea Cycle Disorder (UCD) Drugs Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global Urea Cycle Disorder (UCD) Drugs Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for Urea Cycle Disorder (UCD) Drugs in 2025
  3.2.3 Global Concentration Ratios (CR8) for Urea Cycle Disorder (UCD) Drugs in 2025
3.3 Urea Cycle Disorder (UCD) Drugs Company Evaluation Quadrant
3.4 Urea Cycle Disorder (UCD) Drugs Market: Overall Company Footprint Analysis
  3.4.1 Urea Cycle Disorder (UCD) Drugs Market: Region Footprint
  3.4.2 Urea Cycle Disorder (UCD) Drugs Market: Company Product Type Footprint
  3.4.3 Urea Cycle Disorder (UCD) Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Urea Cycle Disorder (UCD) Drugs Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: Urea Cycle Disorder (UCD) Drugs Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
  4.1.2 United States VS China: Urea Cycle Disorder (UCD) Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Urea Cycle Disorder (UCD) Drugs Consumption Value Comparison
  4.2.1 United States VS China: Urea Cycle Disorder (UCD) Drugs Consumption Value Comparison (2021 & 2025 & 2032)
  4.2.2 United States VS China: Urea Cycle Disorder (UCD) Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Urea Cycle Disorder (UCD) Drugs Companies and Market Share, 2021-2026
  4.3.1 United States Based Urea Cycle Disorder (UCD) Drugs Companies, Headquarters (States, Country)

+357 96 030922
info@marketpublishers.com

4.3.2 United States Based Companies Urea Cycle Disorder (UCD) Drugs Revenue, (2021-2026)
4.4 China Based Companies Urea Cycle Disorder (UCD) Drugs Revenue and Market Share, 2021-2026
4.4.1 China Based Urea Cycle Disorder (UCD) Drugs Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Urea Cycle Disorder (UCD) Drugs Revenue, (2021-2026)
4.5 Rest of World Based Urea Cycle Disorder (UCD) Drugs Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Urea Cycle Disorder (UCD) Drugs Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Urea Cycle Disorder (UCD) Drugs Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE
5.1 World Urea Cycle Disorder (UCD) Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Nitrogen Scavengers
5.2.2 Urea Cycle Activators
5.2.3 Enzyme Therapies
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Urea Cycle Disorder (UCD) Drugs Market Size by Type (2021-2026)
5.3.2 World Urea Cycle Disorder (UCD) Drugs Market Size by Type (2027-2032)
5.3.3 World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY ACTIVE INGREDIENT
6.1 World Urea Cycle Disorder (UCD) Drugs Market Size Overview by Active Ingredient: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Active Ingredient
6.2.1 Glycerol Phenylbutyrate
6.2.2 Sodium Phenylbutyrate
6.2.3 Sodium Phenylacetate and Benzoate
6.2.4 Carglumic Acid
6.2.5 Other
6.3 Market Segment by Active Ingredient

+357 96 030922
info@marketpublishers.com

6.3.1 World Urea Cycle Disorder (UCD) Drugs Market Size by Active Ingredient (2021-2026)
6.3.2 World Urea Cycle Disorder (UCD) Drugs Market Size by Active Ingredient (2027-2032)
6.3.3 World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Active Ingredient (2027-2032)

7 MARKET ANALYSIS BY ADMINISTRATION ROUTE
7.1 World Urea Cycle Disorder (UCD) Drugs Market Size Overview by Administration Route: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Administration Route
7.2.1 Oral
7.2.2 Intravenous
7.2.3 Subcutaneous
7.3 Market Segment by Administration Route
7.3.1 World Urea Cycle Disorder (UCD) Drugs Market Size by Administration Route (2021-2026)
7.3.2 World Urea Cycle Disorder (UCD) Drugs Market Size by Administration Route (2027-2032)
7.3.3 World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Administration Route (2027-2032)

8 MARKET ANALYSIS BY APPLICATION
8.1 World Urea Cycle Disorder (UCD) Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Urea Cycle Disorder (UCD) Drugs Market Size by Application (2021-2026)
8.3.2 World Urea Cycle Disorder (UCD) Drugs Market Size by Application (2027-2032)
8.3.3 World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES
9.1 Amgen
9.1.1 Amgen Details
9.1.2 Amgen Major Business

+357 96 030922
info@marketpublishers.com

9.1.3 Amgen Urea Cycle Disorder (UCD) Drugs Product and Services
9.1.4 Amgen Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Amgen Recent Developments/Updates
9.1.6 Amgen Competitive Strengths & Weaknesses
9.2 Ucyclyd Pharma
9.2.1 Ucyclyd Pharma Details
9.2.2 Ucyclyd Pharma Major Business
9.2.3 Ucyclyd Pharma Urea Cycle Disorder (UCD) Drugs Product and Services
9.2.4 Ucyclyd Pharma Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Ucyclyd Pharma Recent Developments/Updates
9.2.6 Ucyclyd Pharma Competitive Strengths & Weaknesses
9.3 Recordati
9.3.1 Recordati Details
9.3.2 Recordati Major Business
9.3.3 Recordati Urea Cycle Disorder (UCD) Drugs Product and Services
9.3.4 Recordati Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Recordati Recent Developments/Updates
9.3.6 Recordati Competitive Strengths & Weaknesses
9.4 Immedica Pharma
9.4.1 Immedica Pharma Details
9.4.2 Immedica Pharma Major Business
9.4.3 Immedica Pharma Urea Cycle Disorder (UCD) Drugs Product and Services
9.4.4 Immedica Pharma Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Immedica Pharma Recent Developments/Updates
9.4.6 Immedica Pharma Competitive Strengths & Weaknesses
9.5 MPerium
9.5.1 MPerium Details
9.5.2 MPerium Major Business
9.5.3 MPerium Urea Cycle Disorder (UCD) Drugs Product and Services
9.5.4 MPerium Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 MPerium Recent Developments/Updates
9.5.6 MPerium Competitive Strengths & Weaknesses
9.6 Medunik
9.6.1 Medunik Details

+357 96 030922
info@marketpublishers.com

9.6.2 Medunik Major Business
9.6.3 Medunik Urea Cycle Disorder (UCD) Drugs Product and Services
9.6.4 Medunik Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Medunik Recent Developments/Updates
9.6.6 Medunik Competitive Strengths & Weaknesses
9.7 Zevra Therapeutics
9.7.1 Zevra Therapeutics Details
9.7.2 Zevra Therapeutics Major Business
9.7.3 Zevra Therapeutics Urea Cycle Disorder (UCD) Drugs Product and Services
9.7.4 Zevra Therapeutics Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Zevra Therapeutics Recent Developments/Updates
9.7.6 Zevra Therapeutics Competitive Strengths & Weaknesses
9.8 Mallinckrodt
9.8.1 Mallinckrodt Details
9.8.2 Mallinckrodt Major Business
9.8.3 Mallinckrodt Urea Cycle Disorder (UCD) Drugs Product and Services
9.8.4 Mallinckrodt Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Mallinckrodt Recent Developments/Updates
9.8.6 Mallinckrodt Competitive Strengths & Weaknesses
9.9 Lupin
9.9.1 Lupin Details
9.9.2 Lupin Major Business
9.9.3 Lupin Urea Cycle Disorder (UCD) Drugs Product and Services
9.9.4 Lupin Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Lupin Recent Developments/Updates
9.9.6 Lupin Competitive Strengths & Weaknesses
9.10 Grand Pharmaceutical Group
9.10.1 Grand Pharmaceutical Group Details
9.10.2 Grand Pharmaceutical Group Major Business
9.10.3 Grand Pharmaceutical Group Urea Cycle Disorder (UCD) Drugs Product and Services
9.10.4 Grand Pharmaceutical Group Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Grand Pharmaceutical Group Recent Developments/Updates
9.10.6 Grand Pharmaceutical Group Competitive Strengths & Weaknesses

+357 96 030922
info@marketpublishers.com

9.11 Lee's Pharmaceutical Holdings
9.11.1 Lee's Pharmaceutical Holdings Details
9.11.2 Lee's Pharmaceutical Holdings Major Business
9.11.3 Lee's Pharmaceutical Holdings Urea Cycle Disorder (UCD) Drugs Product and Services
9.11.4 Lee's Pharmaceutical Holdings Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Lee's Pharmaceutical Holdings Recent Developments/Updates
9.11.6 Lee's Pharmaceutical Holdings Competitive Strengths & Weaknesses
9.12 Winhealth Pharma Group
9.12.1 Winhealth Pharma Group Details
9.12.2 Winhealth Pharma Group Major Business
9.12.3 Winhealth Pharma Group Urea Cycle Disorder (UCD) Drugs Product and Services
9.12.4 Winhealth Pharma Group Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Winhealth Pharma Group Recent Developments/Updates
9.12.6 Winhealth Pharma Group Competitive Strengths & Weaknesses
9.13 Ultragenyx
9.13.1 Ultragenyx Details
9.13.2 Ultragenyx Major Business
9.13.3 Ultragenyx Urea Cycle Disorder (UCD) Drugs Product and Services
9.13.4 Ultragenyx Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Ultragenyx Recent Developments/Updates
9.13.6 Ultragenyx Competitive Strengths & Weaknesses
9.14 Arcturus Therapeutics
9.14.1 Arcturus Therapeutics Details
9.14.2 Arcturus Therapeutics Major Business
9.14.3 Arcturus Therapeutics Urea Cycle Disorder (UCD) Drugs Product and Services
9.14.4 Arcturus Therapeutics Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Arcturus Therapeutics Recent Developments/Updates
9.14.6 Arcturus Therapeutics Competitive Strengths & Weaknesses
9.15 iECURE
9.15.1 iECURE Details
9.15.2 iECURE Major Business
9.15.3 iECURE Urea Cycle Disorder (UCD) Drugs Product and Services
9.15.4 iECURE Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market

+357 96 030922
info@marketpublishers.com

Share (2021-2026)
9.15.5 iECURE Recent Developments/Updates
9.15.6 iECURE Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS
10.1 Urea Cycle Disorder (UCD) Drugs Industry Chain
10.2 Urea Cycle Disorder (UCD) Drugs Upstream Analysis
10.3 Urea Cycle Disorder (UCD) Drugs Midstream Analysis
10.4 Urea Cycle Disorder (UCD) Drugs Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Urea Cycle Disorder (UCD) Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Urea Cycle Disorder (UCD) Drugs Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Urea Cycle Disorder (UCD) Drugs Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Urea Cycle Disorder (UCD) Drugs Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Urea Cycle Disorder (UCD) Drugs Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Urea Cycle Disorder (UCD) Drugs Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Urea Cycle Disorder (UCD) Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Urea Cycle Disorder (UCD) Drugs Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Urea Cycle Disorder (UCD) Drugs Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Urea Cycle Disorder (UCD) Drugs Players in 2025
Table 12. World Urea Cycle Disorder (UCD) Drugs Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Urea Cycle Disorder (UCD) Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Urea Cycle Disorder (UCD) Drugs Players
Table 15. Urea Cycle Disorder (UCD) Drugs Market: Company Product Type Footprint
Table 16. Urea Cycle Disorder (UCD) Drugs Market: Company Product Application Footprint
Table 17. Urea Cycle Disorder (UCD) Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Urea Cycle Disorder (UCD) Drugs Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Urea Cycle Disorder (UCD) Drugs Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Urea Cycle Disorder (UCD) Drugs Companies, Headquarters (States, Country)

+357 96 030922
info@marketpublishers.com

Table 21. United States Based Companies Urea Cycle Disorder (UCD) Drugs Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Urea Cycle Disorder (UCD) Drugs Revenue Market Share (2021-2026)
Table 23. China Based Urea Cycle Disorder (UCD) Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Urea Cycle Disorder (UCD) Drugs Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Urea Cycle Disorder (UCD) Drugs Revenue Market Share (2021-2026)
Table 26. Rest of World Based Urea Cycle Disorder (UCD) Drugs Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Urea Cycle Disorder (UCD) Drugs Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Urea Cycle Disorder (UCD) Drugs Revenue Market Share (2021-2026)
Table 29. World Urea Cycle Disorder (UCD) Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Urea Cycle Disorder (UCD) Drugs Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Urea Cycle Disorder (UCD) Drugs Market Size by Type (2027-2032) & (USD Million)
Table 32. World Urea Cycle Disorder (UCD) Drugs Market Size by Active Ingredient, (USD Million), 2021 & 2025 & 2032
Table 33. World Urea Cycle Disorder (UCD) Drugs Market Size Value by Active Ingredient (2021-2026) & (USD Million)
Table 34. World Urea Cycle Disorder (UCD) Drugs Market Size by Active Ingredient (2027-2032) & (USD Million)
Table 35. World Urea Cycle Disorder (UCD) Drugs Market Size by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 36. World Urea Cycle Disorder (UCD) Drugs Market Size Value by Administration Route (2021-2026) & (USD Million)
Table 37. World Urea Cycle Disorder (UCD) Drugs Market Size by Administration Route (2027-2032) & (USD Million)
Table 38. World Urea Cycle Disorder (UCD) Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Urea Cycle Disorder (UCD) Drugs Market Size by Application (2021-2026) & (USD Million)
Table 40. World Urea Cycle Disorder (UCD) Drugs Market Size by Application

+357 96 030922
info@marketpublishers.com

(2027-2032) & (USD Million)
Table 41. Amgen Basic Information, Manufacturing Base and Competitors
Table 42. Amgen Major Business
Table 43. Amgen Urea Cycle Disorder (UCD) Drugs Product and Services
Table 44. Amgen Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Amgen Recent Developments/Updates
Table 46. Amgen Competitive Strengths & Weaknesses
Table 47. Ucyclyd Pharma Basic Information, Manufacturing Base and Competitors
Table 48. Ucyclyd Pharma Major Business
Table 49. Ucyclyd Pharma Urea Cycle Disorder (UCD) Drugs Product and Services
Table 50. Ucyclyd Pharma Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Ucyclyd Pharma Recent Developments/Updates
Table 52. Ucyclyd Pharma Competitive Strengths & Weaknesses
Table 53. Recordati Basic Information, Manufacturing Base and Competitors
Table 54. Recordati Major Business
Table 55. Recordati Urea Cycle Disorder (UCD) Drugs Product and Services
Table 56. Recordati Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Recordati Recent Developments/Updates
Table 58. Recordati Competitive Strengths & Weaknesses
Table 59. Immedica Pharma Basic Information, Manufacturing Base and Competitors
Table 60. Immedica Pharma Major Business
Table 61. Immedica Pharma Urea Cycle Disorder (UCD) Drugs Product and Services
Table 62. Immedica Pharma Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Immedica Pharma Recent Developments/Updates
Table 64. Immedica Pharma Competitive Strengths & Weaknesses
Table 65. MPerium Basic Information, Manufacturing Base and Competitors
Table 66. MPerium Major Business
Table 67. MPerium Urea Cycle Disorder (UCD) Drugs Product and Services
Table 68. MPerium Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. MPerium Recent Developments/Updates
Table 70. MPerium Competitive Strengths & Weaknesses
Table 71. Medunik Basic Information, Manufacturing Base and Competitors
Table 72. Medunik Major Business
Table 73. Medunik Urea Cycle Disorder (UCD) Drugs Product and Services

+357 96 030922
info@marketpublishers.com

Table 74. Medunik Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Medunik Recent Developments/Updates
Table 76. Medunik Competitive Strengths & Weaknesses
Table 77. Zevra Therapeutics Basic Information, Manufacturing Base and Competitors
Table 78. Zevra Therapeutics Major Business
Table 79. Zevra Therapeutics Urea Cycle Disorder (UCD) Drugs Product and Services
Table 80. Zevra Therapeutics Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Zevra Therapeutics Recent Developments/Updates
Table 82. Zevra Therapeutics Competitive Strengths & Weaknesses
Table 83. Mallinckrodt Basic Information, Manufacturing Base and Competitors
Table 84. Mallinckrodt Major Business
Table 85. Mallinckrodt Urea Cycle Disorder (UCD) Drugs Product and Services
Table 86. Mallinckrodt Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Mallinckrodt Recent Developments/Updates
Table 88. Mallinckrodt Competitive Strengths & Weaknesses
Table 89. Lupin Basic Information, Manufacturing Base and Competitors
Table 90. Lupin Major Business
Table 91. Lupin Urea Cycle Disorder (UCD) Drugs Product and Services
Table 92. Lupin Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Lupin Recent Developments/Updates
Table 94. Lupin Competitive Strengths & Weaknesses
Table 95. Grand Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 96. Grand Pharmaceutical Group Major Business
Table 97. Grand Pharmaceutical Group Urea Cycle Disorder (UCD) Drugs Product and Services
Table 98. Grand Pharmaceutical Group Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Grand Pharmaceutical Group Recent Developments/Updates
Table 100. Grand Pharmaceutical Group Competitive Strengths & Weaknesses
Table 101. Lee's Pharmaceutical Holdings Basic Information, Manufacturing Base and Competitors
Table 102. Lee's Pharmaceutical Holdings Major Business
Table 103. Lee's Pharmaceutical Holdings Urea Cycle Disorder (UCD) Drugs Product and Services

+357 96 030922
info@marketpublishers.com

Table 104. Lee's Pharmaceutical Holdings Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Lee's Pharmaceutical Holdings Recent Developments/Updates
Table 106. Lee's Pharmaceutical Holdings Competitive Strengths & Weaknesses
Table 107. Winhealth Pharma Group Basic Information, Manufacturing Base and Competitors
Table 108. Winhealth Pharma Group Major Business
Table 109. Winhealth Pharma Group Urea Cycle Disorder (UCD) Drugs Product and Services
Table 110. Winhealth Pharma Group Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Winhealth Pharma Group Recent Developments/Updates
Table 112. Winhealth Pharma Group Competitive Strengths & Weaknesses
Table 113. Ultragenyx Basic Information, Manufacturing Base and Competitors
Table 114. Ultragenyx Major Business
Table 115. Ultragenyx Urea Cycle Disorder (UCD) Drugs Product and Services
Table 116. Ultragenyx Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Ultragenyx Recent Developments/Updates
Table 118. Ultragenyx Competitive Strengths & Weaknesses
Table 119. Arcturus Therapeutics Basic Information, Manufacturing Base and Competitors
Table 120. Arcturus Therapeutics Major Business
Table 121. Arcturus Therapeutics Urea Cycle Disorder (UCD) Drugs Product and Services
Table 122. Arcturus Therapeutics Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Arcturus Therapeutics Recent Developments/Updates
Table 124. Arcturus Therapeutics Competitive Strengths & Weaknesses
Table 125. iECURE Basic Information, Manufacturing Base and Competitors
Table 126. iECURE Major Business
Table 127. iECURE Urea Cycle Disorder (UCD) Drugs Product and Services
Table 128. iECURE Urea Cycle Disorder (UCD) Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. iECURE Recent Developments/Updates
Table 130. iECURE Competitive Strengths & Weaknesses
Table 131. Global Key Players of Urea Cycle Disorder (UCD) Drugs Upstream (Raw Materials)
Table 132. Global Urea Cycle Disorder (UCD) Drugs Typical Customers

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Urea Cycle Disorder (UCD) Drugs Picture
Figure 2. World Urea Cycle Disorder (UCD) Drugs Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Urea Cycle Disorder (UCD) Drugs Total Revenue (2021-2032) & (USD Million)
Figure 4. World Urea Cycle Disorder (UCD) Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Urea Cycle Disorder (UCD) Drugs Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Urea Cycle Disorder (UCD) Drugs Revenue (2021-2032) & (USD Million)
Figure 13. Urea Cycle Disorder (UCD) Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 16. World Urea Cycle Disorder (UCD) Drugs Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 18. China Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032) & (USD Million)

+357 96 030922
info@marketpublishers.com

Figure 20. Japan Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 23. India Urea Cycle Disorder (UCD) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Urea Cycle Disorder (UCD) Drugs by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Urea Cycle Disorder (UCD) Drugs Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Urea Cycle Disorder (UCD) Drugs Markets in 2025
Figure 27. United States VS China: Urea Cycle Disorder (UCD) Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Urea Cycle Disorder (UCD) Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Urea Cycle Disorder (UCD) Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Type in 2025
Figure 31. Nitrogen Scavengers
Figure 32. Urea Cycle Activators
Figure 33. Enzyme Therapies
Figure 34. Other
Figure 35. World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Type (2021-2032)
Figure 36. World Urea Cycle Disorder (UCD) Drugs Market Size by Active Ingredient, (USD Million), 2021 & 2025 & 2032
Figure 37. World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Active Ingredient in 2025
Figure 38. Glycerol Phenylbutyrate
Figure 39. Sodium Phenylbutyrate
Figure 40. Sodium Phenylacetate and Benzoate
Figure 41. Carglumic Acid
Figure 42. Other
Figure 43. World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Active Ingredient (2021-2032)

+357 96 030922
info@marketpublishers.com

Figure 44. World Urea Cycle Disorder (UCD) Drugs Market Size by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 45. World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Administration Route in 2025
Figure 46. Oral
Figure 47. Intravenous
Figure 48. Subcutaneous
Figure 49. World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Administration Route (2021-2032)
Figure 50. World Urea Cycle Disorder (UCD) Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Application in 2025
Figure 52. Hospital
Figure 53. Clinic
Figure 54. Other
Figure 55. World Urea Cycle Disorder (UCD) Drugs Market Size Market Share by Application (2021-2032)
Figure 56. Urea Cycle Disorder (UCD) Drugs Industrial Chain
Figure 57. Methodology
Figure 58. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Urea Cycle Disorder (UCD) Drugs Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GEE90C41A55EEN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GEE90C41A55EEN.html